Analgesics Companies, Corporate Growth and Market Trends Analysis

Top Companies in the Analgesics Market

• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• GlaxoSmithKline plc (GSK)
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Bayer AG
• Eli Lilly and Company
• Bristol-Myers Squibb
• Sanofi S.A.
• Endo International plc
• Mundipharma International Limited
• Grunenthal GmbH
• AbbVie Inc.
• Amgen Inc.
• Hikma Pharmaceuticals
• Aurobindo Pharma Limited
• Alembic Pharmaceuticals
• Cadila Healthcare Ltd.
• Sun Pharmaceutical Industries Ltd.

Market Growth

The global analgesics market size is calculated at USD 43.8 billion in 2024, grew to USD 46.53 billion in 2025, and is projected to reach around USD 80.26 billion by 2034. The market is expanding at a CAGR of 6.24% between 2025 and 2034.

Value Chain Analysis – Analgesics Market

R&D

The R&D activities for analgesics involve developing novel medications for pain relief and repurposing licensed drugs for pain relief.

Key Players: Bayer AG, Sanofi, Endo Pharmaceuticals, and Premier Research

Clinical Trials & Regulatory Approvals

Clinical trials are conducted to assess the safety and efficacy of analgesics, which are then approved by several regulatory agencies.

Key Players: Sofpromed, Concentric Analgesics, Ltd., and Tris Pharma

Patient Support & Services

Patient support & services refer to providing personalized care through analgesics and training individuals about the use and benefits of different analgesics.

Latest Announcement by Industry Leaders

Joy Chatterjee, Vice President, Sales and Marketing Head, Consumer Business Unit, Mankind Pharma Ltd., commented that the company’s entry into the topical analgesic market with Nimulid Strong marks a pivotal moment for Mankind Pharma’s consumer business. By focusing on neck pain, the company aims to empower millions of Indians to live and communicate more freely.

Recent Developments in the Analgesics Market

• In August 2025, researchers from Kyoto University developed a novel analgesic, ADRIANA, that selectively blocks α2B-adrenoceptors to suppress pain. Blocking these receptors could elevate noradrenaline levels, leading to activation of α2A-adrenoceptors and subsequent pain relief.
• In January 2025, Xgene Pharmaceutical announced positive results from its Phase 2b clinical trials to evaluate the safety, efficacy, and pharmacokinetics of XG005 oral tablets for acute pain in patients undergoing bunionectomy. The study was conducted in collaboration with Evolution Research Group and Lotus Clinical Research.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com